Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Orion Oyj
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
May 30, 2026
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
April 23, 2026
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
April 20, 2026
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
April 1, 2026